Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cymbalta Superior To SSRIs, Lilly Says; Once-Daily Dosing Not Vital To Uptake

Executive Summary

Lilly's pending SNRI Cymbalta induces remission from depression more often than selective serotonin reuptake inhibitors, Exec VP-Science & Technology Steven Paul, MD, said
Advertisement

Related Content

Lilly Expects Full GMP Inspection After Upgrades To “Building 105”
Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Topics

Advertisement
UsernamePublicRestriction

Register

PS044277

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel